caprotec bioanalytics GmbH, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry (CCMS) platform technology for the analysis of small molecule – protein interactions, announced a second closing of €1 million ($1.4 M) to its Series B financing, increasing total equity for the round to €5 million ($7.2 M). The capital increase was fully subscribed by LBBW Venture Capital GmbH, Stuttgart, joining existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors.
Prof. Dr. Hubert Koster, CEO of caprotec bioanalytics GmbH, commented, “This additional funding from LBBW Venture will allow us to further leverage caprotec’s CCMS technology into additional markets as diagnostics and will put the company in a position to execute several large pharma partnerships at the same time.”
Dr. Harald Poth, Senior Investment Manager of LBBW Venture, added, “caprotec’s CCMS technology has the potential to solve the most expensive problem in the pharmaceutical industry, the failure of drug candidates in clinical trials due to off-target interactions. With caprotec’s functional proteomics platform it is possible to profile small molecule drug – protein interactions, including membrane proteins in the human proteome to reveal possible off-target proteins causing adverse side effects, early in the drug development process and to use that information to structurally optimize the drug candidates.”
Date: May 9, 2011
Source: caprotec bioanalytics GmbH
